Validated stability indicating LC-DAD method for determination of olmesartan medoxomil in tablets exposed to stress conditions

Acta Pharmaceutica Sciencia

Volumn 51, Issue 3, 2009, Pages 323-331

  Sharma, Ritesh N ^a   Pancholi, Shyam S ^a  

^a GANPAT UNIVERSITY   (India)

Author keywords

Liquid chromatography DAD; Olmesartan medoxomil; Stability indicating; Stress degradation

Indexed keywords

ACETONITRILE; METHANOL; OLMESARTAN; PHOSPHORIC ACID; WATER;

ACCURACY; ARTICLE; CONTROLLED STUDY; DIODE; DRUG DEGRADATION; DRUG DETERMINATION; DRUG STABILITY; LIQUID CHROMATOGRAPHY; SENSITIVITY AND SENSIBILITY; SENSITIVITY AND SPECIFICITY; TABLET FORMULATION;

EID: 74749092291     PISSN: 13072080     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Chrysant, S.G., Chrysant, G.S. (2004). Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert. Opin. Pharmacother. 37: 657.
2. Chrysant, S.G., Weber, M.A., Wang, A.C., Hinman, D.J. (2004). Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am. J. Hypertens. 17: 252.
3. Dongyang, L., Pei, H., Nobuka, M., Xiaoming, L., Li, L., Ji, J. (2007). Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B. 856: 190-197.
4. Ewing, G.W. (1995). Instrumental Methods of Chemical Analysis, 5th edn. Lippincott- Raven, Philadelphia.
5. FDA. (1998). Draft guidance for industry: stability testing of drug substances and drug products: FDA, Rockville, MD.
6. ICH. (2003). Stability Testing of new drug substances and products Q1A (R2): International Conference on Harmonization, IFPMA, Geneva, Switzerland.
7. International Conference on Harmonization Draft guidelines on validation of analytical procedures: definitions and terminology, Federal Register, 1995. 60, Switzerland, 11260 Laeis, P., Puchler, K., Kirch, W. 2001. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J. Hypertens. 19: 21-32.
8. Laeis P, Puchler K, Kirch W (2001) J. Hypertens 19 (Suppl 1): S21-S32
9. Lui, D., Hu, P., Matsushima, N., Li, X., Li, L., Jiang, J. 2007. Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry. J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci. 856: 190-197.
10. Murakami, T., Konno, H., Fukutsu, N., Onodera, M., Kawasaki, T., Kusu, F. 2008. Identification of a degradation product in stressed tablets of olmesartan medoxomil by the complementary use of HPLC Hyphenated Techniques. J. Pharm. Biomed. Anal. 47: 553-559.
11. Mustafa, C., Sacide, A. (2007). Development of a CZE Method for the determination of olmesartan Medoxomil in tablets Chromatogr. 66: 929-933.
12. Nakamura, H., Inoue, T., Arakawa, N., Shimuzi, Y., Yoshigae, Y., Fujimori, I., E, Shimakawa., T, Toyoshi., T, Yokoyama. (2005). Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models. Eur. J. Pharmacol. 512: 239-246.
13. Puchler, K., Laeis, E., Gunther, A. (1999). Safety, tolerability and efficacy of the new oral angiotensin II (AT1)-receptor antagonist CS-866 in patients with mild to moderate hypertension. J. Hum. Hypertens. 13:S4.
14. Rane, V.P., Patil, K.R., Sangshetti, J.N., Yeole, R.D., Shinde, D.B. (2009). Stability-indicating LC method for the determination of olmesartan in bulk drug and in pharmaceutical dosage form. Chromatogra. 69: 169-173.
15. Vaidya, V.V., Roy, S.M.N.,Yetal, S.M., Joshi, S.S., Parekh, S.A. (2008). LC-MS-MS determination of olmesartan in human plasma. Chromatogr. 67:147-150.
16. Zhao, Z., Wang, Q., Tsai, E.W., Qin, X.Z., Ip, D. 1999. Identification of losartan degradates in stressed tablets by LC-MS and LC-MS/MS. J. Pharm. Biomed. Anal. 20: 129-36.